Trial Profile
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Capecitabine; Pembrolizumab
- Indications Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms TROPION-Breast03
- Sponsors AstraZeneca; AstraZeneca AB
- 06 Jul 2023 Planned End Date changed from 26 Mar 2030 to 27 Mar 2030.
- 23 May 2023 Planned End Date changed from 27 Mar 2030 to 26 Mar 2030.
- 20 Dec 2022 Planned End Date changed from 29 Mar 2030 to 27 Mar 2030.